Product Description
Mechanisms of Action: IAV Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Russia | Ukraine
Approved Indications: None
Known Adverse Events: None
Company: Joint Stock Company "Farmak"
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Influenza, Human|COVID-19
Phase 2: Influenza, Human
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
FK/FAV00А-CoV/2020 | P3 |
Completed |
COVID-19 |
2021-03-26 |
40% |
2010-018564-17 | P2 |
Terminated |
Influenza, Human |
2011-04-13 |
|
AM-STP-2-2008 | P3 |
Completed |
Influenza, Human |
2010-01-28 |
26% |